A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

Author： Seiwert T. Y.   Darga T.   Haraf D.   Blair E. A.   Stenson K.   Cohen E. E. W.   Salama J. K.   Villaflor V.   Witt M. E.   Lingen M. W.   Weichselbaum R. R.   Vokes E. E.  

Publisher： Oxford University Press

ISSN： 0923-7534

Source： Annals of Oncology, Vol.24, Iss.3, 2013-03, pp. : 769-776

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93)

By Rathore Ritesh   Birnbaum Ariel   Rathore Bharti   DiPetrillo Thomas   Kennedy Teresa   Ready Neal  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1013-1017

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer

By Marshall John   Shapiro Geoffrey I   Uttenreuther-Fischer Martina   Ould-Kaci Mahmoud   Stopfer Peter   Gordon Michael S  

Future Oncology, Vol. 9, Iss. 2, 2013-02 ,pp. : 271-281

Future Medicine

Access to resources Recommend Favorite

Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer

By Mukai Hirofumi   Takahashi Shunji   Nozawa Masahiro   Onozawa Yusuke   Miyazaki Jun   Ohno Keiji   Suzuki Kazuhiro  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 703-710

Springer Publishing Company

Access to resources Recommend Favorite

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

By  

International Journal of Oncology, Vol. 45, Iss. 6, 2014-01 ,pp. : 2221-2231

Spandidos Publications

Access to resources Recommend Favorite

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite